Medical Advocates

Rilpivirine (Edurant)
 
Journal Abstracts, Papers, and Commentaries

General Reports                         Prophylaxis
Pharmacokinetics

Diagnostics/Monitoring
Viral Dynamics
Resistance
Efficacy

Adverse Events
Drug/Drug Interactions
Therapeutic Strategies


Rilpivirine Main Page Main New/Noteworthy Home Page      

Last Update:  September 30, 2014
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
 

 
Recent advances in rilpivirine: new data and promising treatment option.
Casado JL, Bańón S.
AIDS Rev. 2014 Jul-Sep;16(3):172-81
Abstract

Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz.
BBlas-García A, Polo M, Alegre F, et al  
J Antimicrob Chemother
. 2014 Jul 9
Abstract

E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settings.
Sluis-Cremer N, Jordan MR, Huber K, et al
Antiviral Res
. 2014 Apr 15

Abstract

Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor.
Ripamonti D, Bombana E, Rizzi M.
Expert Rev Anti Infect Ther
. 2013 Nov 28
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
Custodio JM, Yin X, Hepner M,  et al
J Clin Pharmacol
. 2013 Oct 19

Abstract

A WEEK-IN-REVIEW FEATURED REPORT
An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naďve patients.
Putcharoen O, Kerr SJ, Ruxrungtham K.
HIV AIDS (Auckl)
. 2013 Sep 16;5:231-241.
Abstract

Rilpivirine inhibits drug transporters ABCB1, SLC22A1 and SLC22A2 in vitro.
Moss DM, Liptrott NJ, Curley P, et al 
Antimicrob Agents Chemother
. 2013 Sep 3

Abstract

Safety profile of rilpivirine: general and neuropsychiatric tolerability, safety in patients with hepatitis B or C viruses, and lipid profile.
López Cortés LF, Martínez E, von Wichmann MA.
Enferm Infecc Microbiol Clin
. 2013 Jun;31S2:6-11
Abstract

Rilpivirine - a novel HIV-1 non-nucleoside reverse transcriptase inhibitor
Snopková S, Havlíčková K, Polák P, Slesinger P, Husa P.
Klin Mikrobiol Infekc Lek. 2013 Mar;19(1):19-22.
Abstract

The Role of Rilpivirine in Clinical Practice: Strengths and Weaknesses of the New Nonnucleoside Reverse Transcriptase Inhibitor for HIV Therapy.
Imaz A, Podzamczer D.
AIDS Rev. 2012 Oct;14(4):268-78.
Abstract

Absence of a pharmacokinetic interaction of rilpivirine with the P-glycoprotein substrate digoxin in healthy volunteers.
Crauwels H, Deckx H, Enweonye I,  et al
J Int AIDS Soc
. 2012 Nov 11;15(6):18337.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT 
Update on rilpivirine: A new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication.
Zaharatos GJ, Wainberg MA.
Ann Med
. 2012 Nov 17.
Abstract

Rilpivirine. First-line treatment of HIV infection: efavirenz is better documented.

[No authors listed]
Prescrire Int. 2012 Nov;21(132):262-5

Abstract

A WEEK-IN-REVIEW FEATURED REPORT 
Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor.
Sharma M, Saravolatz LD.
J Antimicrob Chemother
. 2012 Oct 25
Abstract

Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.
Schafer JJ, Short WR.
Antivir Ther. 2012 Jul 25.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE

Rilpivirine: A second-generation nonnucleoside reverse transcriptase inhibitor.
James C, Preininger L, Sweet M.
Am J Health Syst Pharm. 2012 May 15;69(10):857-61.
Paper

Rilpivirine and complera: new first-line treatment options.
O'Neal R.
BETA
. 2011 Fall-Winter;23(4):14-8.
Abstract

Rilpivirine: A second-generation nonnucleoside reverse transcriptase inhibitor.
James C, Preininger L, Sweet M.
Am J Health Syst Pharm
. 2012 May 15;69(10):857-61.
Abstract

Rilpivirine : a next-generation non-nucleoside analogue for the treatment of HIV infection.
Fernández-Montero JV, Vispo E,  et al
Expert Opin Pharmacother. 2012 May;13(7):1007-14
Abstract

Rilpivirine.
Sanford M.
Drugs
. 2012 Mar 5;72(4):525-41
Abstract

Rilpivirine: a new addition to the anti-HIV-1 armamentarium.
Miller CD, Crain J, Tran B, Patel N.
Drugs Today (Barc). 2011 Jan;47(1):5-15
Abstract

Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine (TMC125) and Rilpivirine (TMC278): Implications for Drug Design.
Lansdon EB, Brendza KM, Hung M, et al  
J Med Chem
. 2010 May 3
Abstract

Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.
Arastéh K, Rieger A, Yeni P, et al 
Antivir Ther
. 2009;14(5):713-22
Abstract

Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor.
Garvey L, Winston A.
Expert Opin Investig Drugs. 2009 Jul;18(7):1035-4
Abstract
 
Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.
Baert L, van 't Klooster G, Dries W, et al
Eur J Pharm Biopharm
. 2009 Mar 27
Abstract

Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
Fulco PP, McNicholl IR.
Pharmacotherapy
2009 Mar;29(3):281-94
Abstract


Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
Ripamonti D, Maggiolo F.
Curr Opin Investig Drugs. 2008 Aug;9(8):899-912.
Abstract
 
Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies.
Van Gyseghem E, Pendela M, Baert L, et al
Eur J Pharm Biopharm. 2008 Jul 9.
Abstract
 
High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.
Das K, Bauman JD, Clark AD Jr,
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1466-71.
Paper
 
FULL-TEXT PDF ARTICLE
Two-dimensional infrared spectra reveal relaxation of the nonnucleoside inhibitor TMC278 complexed with HIV-1 reverse transcriptase.
Fang C, Bauman JD, Das K, et al
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1472-7.
Paper
 
Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.
Goebel F, Yakovlev A, Pozniak AL, et al
AIDS. 2006 Aug 22;20(13):1721-6.
Abstract

 
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile  (R278474, rilpivirine).
Janssen PA, Lewi PJ, Arnold E, et al
J Med Chem. 2005 Mar 24;48(6):1901-9.
Abstract


Pharmacokinetics
 

  Mechanism of action and pharmacokinetics of rilpivirine.
Portilla J, Estrada V.
Enferm Infecc Microbiol Clin. 2013 Jun;31S2:2-5.
Abstract

Effect of food on the pharmacokinetics of emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen.
Ramanathan S, Custodio J, Yin X, Hepner M,  et al  
J Int AIDS Soc
. 2012 Nov 11;15(6):18333.
Abstract

FULL-TEXT ARTICLE
Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation.
van 't Klooster G, Hoeben E, Borghys H,
Antimicrob Agents Chemother
. 2010 May;54(5):2042-50.
Paper


Diagnostics/Monitoring
 

 
A liquid chromatography-tandem mass spectrometry assay for quantification of rilpivirine and dolutegravir in human plasma.
Grégoire M, Deslandes G, Renaud C,  et al
J Chromatogr B Analyt Technol Biomed Life Sci
. 2014 Sep 16;971C:1-9
Abstract

A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
Aouri M, Calmy A, Hirschel B,  et al 
J Mass Spectrom
. 2013 May;48(5):616-625.
Abstract

A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
Aouri M, Calmy A, Hirschel B,  et al 
J Mass Spectrom. 2013 May;48(5):616-625.

Abstract

Determination of rilpivirine (TMC-278) plasma concentrations by the conventional LC-MS method.
Shibata M, Takahashi M, Kuwahara T, et al
J Int AIDS Soc
. 2012 Nov 11;15(6):18361
Abstract

Liquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma.
Burugula L, Pilli NR, Makula A,  et al
Biomed Chromatogr
. 2012 Jun 22.
.
Abstract


Viral Dynamics
 

  Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.
Rimsky L, Vingerhoets J, Van Eygen V, et al
J Acquir Immune Defic Syndr
. 2011 Nov 7.
Abstract

Resistance
 

 

Real-life rilpivirine resistance and potential emergence of an E138A-positive HIV strain in north-eastern France.
Jeulin H, Foissac M, Boyer L, et al  
J Antimicrob Chemother
. 2014 Jul 8.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: Analysis from a national drug-resistance database (ARCA).
Rossotti R, Fonte L, Meini G,  et al
J Med Virol. 2014 May 17.
Abstract

Transmitted drug resistance to rilpivirine among antiretroviral-naďve patients living with HIV from northern Poland.
Parczewski M, Urbańska A, Maciejewska K, et al
J Int AIDS Soc. 2014 Apr 17;17(1):18929.

Abstract

Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
Picchio GR, Rimsky LT, Van Eygen V,
Antivir Ther. 2014 Apr 4
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
Lambert-Niclot S, Charpentier C, Storto A, et al
J Antimicrob Chemother
. 2013 Dec 2
Abstract

The Connection Domain Mutation N348I in HIV-1 Reverse Transcriptase Enhances Resistance to Etravirine and Rilpivirine but Restricts the Emergence of the E138K Resistance Mutation by Diminishing Viral Replication Capacity.
Xu HT, Colby-Germinario SP, Oliveira M,  et al
J Virol
. 2013 Nov 13.
Abstract

Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B.
Fofana DB, Soulie C, Maiga AI, et al
J Antimicrob Chemother. 2013 Jul 5.
Abstract

Resistance profile of rilpivirine.
Imaz A, García F, di Yacovo S, Llibre JM.
Enferm Infecc Microbiol Clin. 2013 Jun;31S2:36-43
Abstract

The Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase and their Interactions with the M184I Mutation in Defining Patterns of Resistance to the Non-Nucleoside Reverse Transcriptase Inhibitors Rilpivirine and Etravirine.
Xu HT, Colby-Germinario SP, Asahchop EL, et al 
Antimicrob Agents Chemother
. 2013 Apr 22.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Lambert-Niclot S, Charpentier C, Storto A,  et al
J Antimicrob Chemother
. 2013 Jan 29.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Distinct resistance patterns to etravirine and rilpivirine in viruses containing nnrti mutations at baseline.
Asahchop EL, Wainberg MA, Oliveira M, et al
AIDS. 2012 Dec 19.
Abstract

A WEEK-IN-REVIEW FEATURED ARTICLE

Preexisting mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virologic response.
Vingerhoets J, Rimsky L, Van Eygen V,  et al
Antivir Ther
. 2012 Sep 6.
Abstract

FULL-TEXT PDF ARTICLE
Biochemical Mechanism of HIV-1 Resistance to Rilpivirine.
Singh K, Marchand B, Rai DK,  et al
J Biol Chem. 2012 Sep 6
Paper

Rilpivirine Resistance Mutations in HIV Patients Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Therapies.
Anta L, Llibre JM, Poveda E,  et al
AIDS
. 2012 Aug 7.
Abstract

FULL-TEXT ARTICLE
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
Balamane M, Varghese V, Melikian GL, et al
Antimicrob Agents Chemother. 2012 Aug;56(8):4522-4
Paper
 

Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
Nicot F, Saliou A, Raymond S, et al  J
Clin Virol
. 2012 Jul 19.
Abstract

E138K and M184I mutations in HIV-1 reverse transcriptase co-emerge as a result of APOBEC3 editing in the absence of drug exposure.
Fourati S, Malet I, Lambert S,  et al
AIDS. 2012 Jun 12
Abstract

A WEEK-IN REVIEW FEATURED REPORT
Panel of Prototypical Recombinant Infectious Molecular Clones Resistant to Nevirapine, Efavirenz, Etravirine, and Rilpivirine.
Balamane M, Varghese V, Melikian GL,  et al
Antimicrob Agents Chemother
. 2012 Jun 4.
Abstract

A WEEK-IN REVIEW FEATURED REPORT
Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance Database.
Reinheimer C, Doerr HW, Stürmer M. et al
J Clin Virol
. 2011 Dec 30.
Abstract

   
  Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T, Ananworanich J, Chetchotisakd P,  et al
Antivir Ther. 2011;16(7):1113-21
Abstract

Efficacy
 

 
The Efficacy, Pharmacokinetics and Safety of a Nevirapine to Rilpivirine Switch in Virologically Suppressed HIV-1 Infected Patients.
Rokx C, Blonk M, Verbon A,  et al
J
Acquir Immune Defic Syndr. 2014 Sep 22.
Abstract

Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'
Amiel C, Schneider V, Guessant S,  et al
J Antimicrob Chemother. 2014 Aug 11.
Abstract

Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naďve HIV-1-Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis.
Behrens G, Rijnders B, Nelson M,  et al  
AIDS Patient Care STDS
. 2014 Mar 24.
Abstract

Outcomes In Older Versus Younger Patients Over 96 Weeks In Hiv-1-Infected Patients Treated With Rilpivirine Or Efavirenz In Echo And Thrive
Ryan R, Dayaram YK, Schaible D,  et al
Curr HIV Res
. 2014 Jan 28
Abstract

Data on rilpivirine in treatment-naďve patients. Lessons from ECHO, THRIVE and STaR.
Domingo P, Ribera E.
Enferm Infecc Microbiol Clin. 2013 Jun;31S2:20-29.
Abstract

Rilpivirine Versus Efavirenz in HIV-1-Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies.
Nelson MR, Elion RA, Cohen CJm et al
HIV Clin Trials. 2013 May-Jun;14(3):81-91.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
Rimsky L, Van Eygen V, Hoogstoel A,  et al
Antivir Ther. 2013 May 28
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Rilpivirine : a next-generation non-nucleoside analogue for the treatment of HIV infection.
Fernández-Montero JV, Vispo E,  et al
Expert Opin Pharmacother
. 2012 May;13(7):1007-14
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir.
Wainberg MA.HIV AIDS (Auckl). 2013;5:41-9.
Abstract

Rilpivirine versus efavirenz in HIV-1 patients with baseline viral load ≤100 000 copies/ml: week 48 Phase III analysis.
Molina JM, Clumeck N, Redant K,  et al
AIDS
. 2012 Dec 31.
Abstract

A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants.
Johnson BC, Pauly GT, Rai G, et al
Retrovirology
. 2012 Dec 5;9(1):99.
Abstract

Week 96 efficacy and safety of rilpivirine in treatment-naďve, HIV-1 patients in two Phase III randomised trials.
Cohen CJ, Molina JM, Cassetti I, et al
AIDS
. 2012 Dec 3.
Abstract

Rilpivirine. First-line treatment of HIV infection: efavirenz is better documented.
[No authors listed]
Prescrire Int. 2012 Nov;21(132):262-5
Abstract

A WEEK-IN-REVIEW FEATURED ARTICLE
Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era.
De Clercq E.
Biochem Pharmacol
. 2012 Apr 5.
Abstract

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
Nelson M, Amaya G, Clumeck N, et al
J Antimicrob Chemother
. 2012 Apr 24.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naďve, HIV-1-infected patients: Pooled results from the phase 3 double-blind, randomized ECHO and THRIVE trials.
Cohen C, Molina J, Cahn P, et al
J Acquir Immune Defic Syndr
. 2012 Feb 16
Abstract

   
  Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Molina JM, Cahn P, Grinsztejn B. et al
Lancet. 2011 Jul 16;378(9787):238-46.
Abstract
   
  Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Cohen CJ, Andrade-Villanueva J, Clotet B, et al 
Lancet
. 2011 Jul 16;378(9787):229-37.
Abstract
 
  New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
Hughes CA, Robinson L, Tseng A, Macarthur RD.
Expert Opin Pharmacother
. 2009 Aug 13.
Abstract

Adverse Events
 

  A WEEK-IN REVIEW FEATURED REPORT
Analysis of Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1-Infected Adults Treated with Rilpivirine or Efavirenz Over 96 Weeks in the ECHO and THRIVE Trials.
Tebas P, Sension M, Arribas J,  et al
Clin Infect Dis
. 2014 Apr 11.
Abstract

Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO).
Wohl DA, Orkin C, Doroana M,  et al
Antivir Ther. 2014 Jan 16.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Liver Toxicity in HIV-Infected Patients Receiving Novel Second-Generation Nonnucleoside Reverse Transcriptase Inhibitors Etravirine and Rilpivirine.
Casado JL. 
AIDS Rev. 2013 Jul-Sep;15(3):139-45.
Abstract


Drug/Drug Interactions
 

  The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers.
Crauwels HM, van Heeswijk RP, Vandevoorde A,  
J Clin Pharmaco
l
. 2013 Nov 6.
Abstract

Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.
Crauwels HM, van Heeswijk RP, Buelens A,  et al
Int J Clin Pharmacol Ther
. 2013 Oct 28.
Abstract

Lack of Pharmacokinetic Interaction Between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744.
Ford SL, Gould E, Chen S, et al 
Antimicrob Agents Chemother
. 2013 Aug 26.

Abstract

Pharmacokinetic interactions
Arazo Garcés P, Los Santos Gil ID.
Enferm Infecc Microbiol Clin. 2013 Jun;31S2:12-19
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Clinical Perspective on Drug‑Drug Interactions with the Non-nucleoside Reverse Transcriptase Inhibitor Rilpivirine.
Crauwels H, van Heeswijk RP, Stevens M,  et al 
AIDS Rev
. 2013 May 17;15(2):87-101.

Abstract


Therapeutic Strategies
 

  A WEEK-IN-REVEW FEATURED REPORT
Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in effective salvage antiretroviral therapy.
Leporrier J, Etienne M, Chapuzet C, et al
J Clin Virol
. 2014 Aug;60(4):428-30

Abstract

Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.
Rokx C, Verbon A, Rijnders B.
HIV Med. 2014 Apr 16.
Abstract

Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
Mills AM, Cohen C, Dejesus E ,et al
HIV Clin Trials. 2013 Sep-Oct;14(5):216-33.
Abstract

Potential role of rilpivirine in simplification regimens.
Casado JL, Moreno S.
Enferm Infecc Microbiol Clin. 2013 Jun;31S2:30-35.
Abstract

 

Prophylaxis
 

  A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV negative volunteers for pre-exposure prophylaxis (PrEP).
Jackson AG, Else LJ, Mesquita PM,  et al
Clin Pharmacol Ther. 2014 May 26

Abstract

 


Rilpivirine Main Page Main New/Noteworthy Home Page      

 Rilpivirine Journal Citations